Rezulin (troglitazone) is an anti-diabetic and anti-inflammatory drug listed in the class of drugs known as thiazolidinediones.
These drugs improve insulin sensitivity in skeletal muscle and suppress hepatic glucose output. Rezulin was developed by the Japanese company Daiichi Sankyo and introduced and manufactured in the United States by Parke-Davis in the late 1990s.
FDA Approves Rezulin in 1997
The Food and Drug Administration (FDA) approved Rezulin in 1997, despite finding that the drug was potentially harmful to the liver and heart. After Rezulin was approved, dozens of patients were hospitalized with liver-related ailments.